Are Compounded Semaglutide Being Discontinued? What You Need to Know

Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Compounded semaglutide injections have not been discontinued, but the market for these medications has experienced significant changes since 2023. Supply chain pressures, regulatory oversight, and increased demand have created fluctuations in availability and pricing across different providers. PlexusDx remains committed to sourcing compounded semaglutide from licensed 503A compounding pharmacies, ensuring consistent patient access to this weight loss treatment.

Understanding the Compounded Semaglutide Supply Situation

Compounded semaglutide continues to be manufactured and distributed by licensed 503A compounding pharmacies across all 50 states. Unlike brand-name Ozempic or Wegovy, compounded formulations are not subject to FDA approval but must comply with strict pharmacy regulations and quality standards. The perception of discontinuation often stems from temporary shortages at individual providers rather than a complete market halt.

The semaglutide market expanded rapidly between 2021 and 2023 as off-label weight loss use grew beyond diabetic patients. This surge in demand initially outpaced supply capacity at many compounding facilities, leading some patients to experience delays or switching between providers. Current supply chains have largely stabilized, though individual pharmacy availability can vary based on their manufacturing capacity and distribution agreements.

How Regulatory Oversight Affects Compounded Medication Access

The FDA and state pharmacy boards have intensified inspection and compliance efforts for 503A compounding pharmacies since 2023, focusing on sterility, potency, and labeling accuracy. This regulatory attention has eliminated some lower-quality operators but has strengthened the credibility and consistency of remaining licensed facilities. PlexusDx partners exclusively with compounding pharmacies that meet rigorous standards for personnel training, equipment maintenance, and quality assurance protocols.

Recent regulatory guidance has clarified that compounded semaglutide is permissible when a patient cannot access brand-name alternatives or when clinical circumstances warrant customization. This framework has actually protected patient access by distinguishing between legitimate compounding practice and unauthorized manufacturing. Patients receiving treatment from licensed 503A pharmacies benefit from this regulatory framework, which ensures accountability and safety standards.

Why Brand-Name Shortages Led to Compounded Alternatives

Ozempic and Wegovy experienced genuine supply constraints from 2022 through 2023 due to manufacturing limitations at Novo Nordisk facilities. These shortages prompted many patients and providers to explore compounded options as a bridge to treatment access. Unlike the brand-name shortage, compounded semaglutide supply from multiple 503A pharmacies has remained more resilient because it does not depend on a single manufacturer.

The growth of compounded semaglutide market share occurred precisely because it filled a critical access gap during brand-name shortages. As brand-name supply has partially recovered, some patients have continued using compounded formulations due to lower out-of-pocket costs, faster prescription turnaround, and dose customization options. This diversified market has actually stabilized overall access compared to years when Novo Nordisk shortages left patients without options.

How PlexusDx Ensures Reliable Access to Compounded Semaglutide

PlexusDx sources compounded semaglutide exclusively from licensed 503A compounding pharmacies that maintain transparent quality documentation and regulatory compliance records. Each batch undergoes verification for potency, sterility, and pharmaceutical purity before distribution to patients. This vetting process ensures that every patient receives medication meeting pharmaceutical-grade standards regardless of geographic location.

Compounded semaglutide injections at PlexusDx are $189/mo month-to-month, or from $149/mo on the 6-month plan across all commitment tiers, with the pricing principle that your dose may need to go up while your price stays flat. This transparent model eliminates surprise cost escalations as patients advance to therapeutic doses. HSA and FSA funds can be applied to compounded semaglutide purchases, and no insurance coverage or membership fees are required, making treatment accessible across all 50 states.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide actually being discontinued by the FDA?

No. The FDA has not issued discontinuation orders for compounded semaglutide. Regulatory oversight has intensified for quality assurance purposes, but licensed 503A compounding pharmacies continue manufacturing and distributing semaglutide legally. Some individual providers may have exited the market or experienced supply delays, creating localized perception of discontinuation without representing industry-wide shutdown.

What is the difference between 503A and 503B compounding, and why does it matter?

503A compounding pharmacies prepare medications in response to individual patient prescriptions, while 503B facilities manufacture bulk quantities for distribution. PlexusDx uses only licensed 503A compounding pharmacies, which are subject to stricter state pharmacy board oversight and must maintain direct pharmacy-patient relationships. 503A compounding offers greater quality control transparency and regulatory accountability than 503B operations.

Will compounded semaglutide prices increase if supply becomes more restricted?

PlexusDx pricing remains flat regardless of dose escalation, following the principle that your dose may go up while your price won't. Compounded semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan across all commitment tiers, protecting patients from cost uncertainty as their treatment advances. This fixed pricing model shields patients from market volatility in supply and demand.

How do I know if my compounded semaglutide is safe and effective?

Licensed 503A compounding pharmacies must document batch testing for potency, sterility, and purity through independent laboratories or in-house quality assurance. Ask your provider for documentation of pharmaceutical-grade manufacturing standards. PlexusDx sources exclusively from facilities maintaining transparent quality records, and all medications are dispensed with detailed labeling and usage instructions to ensure safe administration.

Can the Precision Peptide Genetic Test help me determine if compounded semaglutide is right for me?

Yes. PlexusDx Precision Peptide Genetic Test ($298) analyzes genetic variants in GIPR and FTO, and MC4R pathways across 14 metabolic pathways and 49 peptides. Results identify individual predispositions to GLP-1 responsiveness, helping optimize whether semaglutide, tirzepatide, or combination therapy best aligns with your genetic profile for sustained weight loss outcomes.

Related Reading

• Genetic Testing 101 What You Need To Know Before Getting Tested
• Compounded Semaglutide 2
• Compounded Semaglutide
• What Genetic Factors Determine How Much Sleep You Need Each Night

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.